Ellina Grigorievna Oganesyan

Ellina Grigorievna Oganesyan

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
OSOlga Shadrivova
Olga Shadrivova
DGDenis Gusev
Denis Gusev
MVMaria Vashukova
Maria Vashukova
DLDmitriy Lobzin
Dmitriy Lobzin
VGVitaliy Gusarov
Vitaliy Gusarov
WGWorking Group
Working Group
We studied the risk factors, etiology, clinical features and the effectiveness of therapy of COVID-19-associated pulmonary aspergillosis (CAPA) in adult patients. In this retrospective study, we included 45 patients with proven (7%) and probable (93%) CAPA. The ECMM/ISHAM, 2020 criteria were used to diagnose CAPA. A case-control study was conducted to study the risk factors of CAPA; the control group included 90 adult COVID-19 patients without IA. In CAPA patients, the main underlying diseases were diabetes mellitus (33%), and hematological and oncological diseases (31%). The probability of CAPA developing significantly increased with lymphocytopenia >10 days (OR = 8.156 (3.056–21.771), p = 0.001), decompensated diabetes mellitus (29% vs. 7%, (OR = 5.688 (1.991–16.246), p = 0.001)), use of glucocorticosteroids (GCS) in prednisolone-equivalent dose > 60 mg/day (OR = 4.493 (1.896–10.647), p = 0.001) and monoclonal antibodies to IL-1ß and IL-6 (OR = 2.880 (1.272–6.518), p = 0.01). The main area of localization of CAPA was the lungs (100%). The clinical features of CAPA were fever (98% vs. 85%, p = 0.007), cough (89% vs. 72%, p = 0.002) and hemoptysis (36% vs. 3%, p = 0.0001). Overall, 71% of patients were in intensive care units (ICU) (median—15.5 (5–60) days), mechanical ventilation was used in 52% of cases, and acute respiratory distress syndrome (ARDS) occurred at a rate of 31%. The lung CT scan features of CAPA were bilateral (93%) lung tissue consolidation (89% vs. 59%, p = 0.004) and destruction (47% vs. 1%, p = 0.00001), and hydrothorax (26% vs. 11%, p = 0.03). The main pathogens were A. fumigatus (44%) and A. niger (31%). The overall survival rate after 12 weeks was 47.2%.

4 January 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
EOEllina Grigorievna Oganesyan
Ellina Grigorievna Oganesyan
VKViktoriia Klimenteva
Viktoriia Klimenteva
IVIrina Vybornova
Irina Vybornova
VVValentina Venchakova
Valentina Venchakova
EPEkaterina Parshikova
Ekaterina Parshikova
ATAnastasia Taraskina
Anastasia Taraskina
Candida auris is an emerging multidrug-resistant fungal pathogen causing nosocomial transmission and invasive infections with high mortality. This study aimed to investigate the genetic relationships, enzymatic activities, and drug-resistance profiles of C. auris isolates to evaluate the population and epidemiological diversity of candidiasis in Russia. A total of 112 clinical isolates of C. auris were analyzed from May 2017 to March 2023 in 18 hospitals across Saint Petersburg, the Leningrad Region, and Moscow. Species identification was confirmed by ITS sequencing, and genotyping was performed using 12 short tandem repeat (STR) markers. Antifungal susceptibility was tested using Sensititre™ YeastOne™ plates, and hydrolytic enzyme production was measured by the plate method. ITS sequencing confirmed that all isolates belonged to a single ITS cluster (clades I and III). Fifteen distinct STR genotypes were identified, with genotype I being dominant (n = 53). The most variable of the analyzed markers turned out to be M3-Ia, which was represented in the Russian population by eight different variants. Fluconazole resistance was found in 111 isolates, 17% were resistant to amphotericin B, and 3.6% to 5-flucytosine. Phospholipase activity was strong in most strains, especially in urine isolates (p = 0.014). Conclusion: The predominance of STR genotype I and its variability at the M3-Ia locus suggest its association with nosocomial outbreaks and transmissibility in Russia.

14 September 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
OKOlga Kozlova
Olga Kozlova
EBEkaterina Burygina
Ekaterina Burygina
SKSofya Khostelidi
Sofya Khostelidi
OSOlga Shadrivova
Olga Shadrivova
ASAndrey Saturnov
Andrey Saturnov
WGWorking Group
Working Group
We studied the risk factors, etiology, clinical manifestations, and treatment outcomes of COVID-19-associated invasive candidiasis (COVID-IC) in adult patients admitted to six medical facilities in St. Petersburg. (November 2020–December 2022). In this retrospective study, we included 72 patients with COVID-IC with a median age of 61 years (range 29–96), 51% of whom were women. The predisposing factors for COVID-IC were a central venous catheter (CVC) for more than 10 days (the odds ratio (OR) = 70 [15–309]), abdominal surgical treatment performed in the previous 2 weeks (OR = 8.8 [1.9–40.3]), bacteremia (OR = 10.6 [4.8–23.3]), pulmonary ventilation (OR = 12.9 [5.9–28.4]), and hemodialysis (OR = 11.5 [2.5–50.8]). The signs and symptoms of COVID-IC were non-specific: fever (59%), renal failure (33%), liver failure (23%), and cardiovascular failure (10%). Candida albicans (41%) predominated among the pathogens of the candidemia. The multidrug-resistant Candida species C. auris (23%) and C. glabrata (5%) were also identified. Empirical therapy was used in 21% of COVID-IC patients: azole-93%, echinocandin–7%. The majority of COVID-IC patients (79%) received, after laboratory confirmation of the diagnosis of IC, fluconazole (47%), voriconazole (25%), echinocandin (26%), and amphotericin B (2)%. The 30 days overall survival rate was 45%. The prognosis worsened concomitant bacteremia, hemodialysis, and long-term therapy by systemic glucocorticosteroids (SGCs), bronchial colonization with Candida spp. The survival prognosis was improved by the early change/replacement of CVC (within 24 h), the initiation of empirical therapy, and the use of echinocandin. Conclusions: We highlighted the risk factors that predispose COVID-19 patients to candidiasis and worsen the survival prognosis. Their individual effects in patients with COVID-19 must be well understood to prevent the development of opportunistic co-infections that drastically lower chances of survival.

19 August 2025 in Cell and Tissue Biology
Verified
Journal Article
Closed access
PDF file
ATAnastasia Taraskina
Anastasia Taraskina
ЕFЕ. V. Frolova
Е. V. Frolova
АUА. Е. Uchevatkina
А. Е. Uchevatkina
EOEllina Grigorievna Oganesyan
Ellina Grigorievna Oganesyan
VVV. V. Venchakova
V. V. Venchakova
NVN. V. Vasilyeva
N. V. Vasilyeva
Vulvovaginal candidiasis (VVC) is an infection that affects up to 75% of women of reproductive age worldwide. In approximately 5–10% of women with VVC, the disease becomes chronic and relapses, with four or more exacerbations per year occurring, negatively affecting their reproductive health and quality of life. A balanced immune response and changes in vaginal biota have been shown to play a central role in maintaining mucosal homeostasis. The consequence of the disruption of this balance is the reprogramming of innate immune responses, hyperactivation of the inflammasome, as well as the difficult-to-control reproduction of Candida fungi, which, in turn, leads to the formation of recurrent VVC (RVVC). However, even though microevolutionary processes that trigger the transition of a commensal organism to a pathogen, biome translocation factors, and molecular mechanisms of interactions between its representatives and the local immune response are critical participants in the pathogenesis of the disease and are of primary importance for the development of promising therapeutic approaches to combat RVVC, they are currently insufficiently studied. The review presents information on the characteristics of the innate and adaptive immune response of the vaginal mucosa, the structure of the microbiome associated with the pathogenesis of RVVC, changes in its microecology, key molecules that determine the homeostasis of the biome and the interactions between its representatives (fungi, bacteria). The virulence factors of the fungal pathogen that determine the development of RVVC are described. The paper also discusses new potential strategies for the treatment and/or prevention of VVC based on the molecular mechanisms of interactions between yeast, vaginal bacterial biota, and the local human immune response.

20 October 2026 in Clinical Microbiology and Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
EOEllina Grigorievna Oganesyan
Ellina Grigorievna Oganesyan
KGK.V. Gusarova
K.V. Gusarova
SKS.V. Kovyrshin
S.V. Kovyrshin
AZA.S. Zhuk
A.S. Zhuk
ATAnastasiya E. Taraskina
Anastasiya E. Taraskina
NVN.V. Vasilyeva
N.V. Vasilyeva
Objective. To develop an in vitro model for the development of Candidozyma auris resistance to flucytosine (5-FC) and characterize its associated mutational profile. Materials and Methods. An adaptive laboratory evolution study was performed on seven clinical C. auris isolates of the South Asian clade obtained from independent epidemiological foci in Russian hospitals. Isolates underwent stepwise selection with increasing 5-FC concentrations, with molecular verification at defined checkpoints. Minimum inhibitory concentrations (MICs) were determined by broth microdilution (EUCAST). The coding sequences of FUR1, FCY1 and FCY2 were Sanger-sequenced and compared with the reference strain B8441. The fitness cost was additionally assessed as the area under the growth curve (AUC) under standard and subinhibitory conditions. Results. In all seven isolates resistance emerged rapidly and reproducibly: by passage P10 the 5-FC MIC rose to > 64 mg/L and persisted through P30. The FCY1 S70R substitution was present in all parental isolates and was not considered adaptive. Resistance was associated mainly with mutations in FUR1 (G68, and also L168F, E182Q) and FCY2 (Y353, G317*); in some lineages high MICs occurred without detectable changes in these genes. Evolved variants (P30) showed reduced growth activity (lower AUC) in the absence of the drug but outgrew parental isolates at the subinhibitory 5-FC concentration. Conclusions. Experimental selection of C. auris in the presence of flucytosine resulted in the rapid and reproducible emergence of high-level resistance, with MICs exceeding 64 mg/L. The resistant phenotype arose independently in several lineages and was associated with distinct alterations in genes involved in 5-FC metabolism, indicating genetic heterogeneity in the underlying adaptive mechanisms. In the absence of the drug, acquired resistance was accompanied by reduced growth, consistent with a fitness cost. However, exposure to a subinhibitory concentration of 5-FC shifted relative fitness in favor of the resistant variants. Thus, sustained exposure to low concentrations of flucytosine may promote the selection of resistant C. auris subpopulations despite their reduced baseline growth capacity.

16 September 2026 in Cell and Tissue Biology
Verified
Journal Article
Closed access
PDF file
EFE. V. Frolova
E. V. Frolova
OSO. V. Sekretareva
O. V. Sekretareva
AUA. E. Uchevatkina
A. E. Uchevatkina
VVV. V. Venchakova
V. V. Venchakova
EBEkaterina Burygina
Ekaterina Burygina
NVN. V. Vasilyeva
N. V. Vasilyeva
Objective: Recurrent vulvovaginal candidiasis (RVVC) is currently considered an immunopathological process. Fungal virulence factors and host immune responses, such as NLRP3 inflammasome activation, are thought to play an important role in the development of hyperinflammation. The aim of this study was to investigate the expression patterns of genes encoding key molecules involved in the immunoregulation of the inflammatory response, C. albicans virulence factors, as well as cytokine levels in the vaginal fluid of patients with RVVC. Materials and methods: Gene expression encoding NLRP3, caspase-1 (CASP1), NLRC4, cytokines IL-1β, IL-18, IL-1Ra, and C. albicans virulence factors was determined in the cellular fraction of vaginal washes by quantitative polymerase chain reaction. The levels of IL-1β, IL-18, IL-22, and IL-1Ra were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed using the Python programming language (pandas, numpy, scipy, statsmodels, and matplotlib libraries). Results: Increased NLRP3 inflammasome activity at the local level in RVVC patients was confirmed by enhanced expression of NLRP3, CASP1, and IL1B genes, as well as elevated IL-1β levels compared to the control group. In all RVVC patients, unlike healthy women, expression of the SAP2 gene, associated with the yeast form of C. albicans, as well as SAP5, SAP6, ECE1, and HWP1 genes associated with the yeast-to-hypha transition, was detected. The important role of candidalysin in NLRP3 inflammasome activation was confirmed by a strong correlation between CASP1 and ECE1 expression. A distinctive feature of women with candidal infection was a significant decrease in vaginal IL-18 and IL-1Ra levels, as well as a tendency toward reduced IL-22 concentrations. A negative correlation was found between IL-18 and IL-22 levels and the number of vulvovaginal candidiasis recurrences per year. Conclusion: In RVVC, the IL-18/IL-22/IL-1Ra axis at the local level counteracts C. albicans virulence factors in NLRP3 inflammasome activation and, consequently, prevents the transition of the inflammatory response to a chronic stage and the progression of fungal infection.